Request Sample

Saudi Arabia Pharmaceutical market has recorded significant growth over the years driven by various factors like increasing ageing population mostly in the above 60 years bracket, changing demographics and rise in the incidence of lifestyle diseases, increased spending power, result driven government initiatives to promote the growth of indigenous pharmaceutical companies. Inspite of the progress, the pharmaceutical sector in the Saudi Arabia is still in an emerging phase, and drug manufacturing is at a relatively nascent stage owing to many challenges, which need to be resolved. The Saudi pharmaceuticals market has accounted for more than to 50% of all pharmaceutical products sales in the GCC region.

Saudi Arabia relies substantially on imports of pharmaceutical products, primarily from Europe, to meet local demand as a result of insufficient domestic drug production and lack of indigenous research capabilities. Government is taking efforts to promote FDI in the pharmaceutical sector especially directed to help development of skills of local companies to manufacture patented medicines as well. Policies like free trade agreements have played a significant role in encouraging foreign investments. Increased penetration of the healthcare sector by insurance providers, price regulation guidelines to ensure uniformity in pricing and dedicated healthcare reforms, have further ensured growth of pharmaceutical market in recent years.

1. Saudi Arabia Pharmaceutical Market Overview
1.1 Current Market Overview
1.2 Drug Pricing System
1.3 Disease Prevalence

2. Pharmaceutical Market by Segment
2.1 Branded Drugs
2.2 Generic drugs
2.3 OTC

3. Favourable Market Dynamics
3.1 Largest Market in Middle East
3.2 Promotion of Domestic Pharmaceutical Industry
3.3 Well Established Regulatory Framework
3.4 Demand for OTC & Generics Drugs
3.5 Import Dependent Market
3.6 Challenges to be Resolved
3.7 Future Growth Avenues

4. Regulatory & Policy Framework
4.1 Drug Approval Process (Generics, Biologicals, Radipharmaceuticals & New Chemical Entity)
4.2 Monoclonal Antibodies and Related Products Quality Guideline
4.3 Law of Pharmaceutical Establishments and Preparations
4.4 Guidelines on Biosimilars
4.4.1 Insulin
4.4.2 Interferons
4.4.3 Erythropoietin
4.4.4 Granulocyte-Colony Stimulating Factor
4.4.5 Human Growth Hormone

5. Competitive Landscape
5.2 Tabuk Pharmaceuticals
5.3 Jamjoom Pharma
5.4 Julphar (Gulf Pharmaceutical Industries)
5.5 GSK
5.6 Pfizer
5.7 Novartis
5.8 Astra

List of Figures

Figure 1-1: Saudi Arabia Pharmaceutical Market (US$ Billion), 2012-2018
Figure 1-2: Saudi Arabia Pharmaceutical Market by Segment (US$ Billion), 2012-2018
Figure 1-3: Saudi Arabia Pharmaceutical Market by Segment (%), 2012 & 2018
Figure 1-4: Factors Driving Growth in Saudi Pharmaceuticals Market
Figure 1-5: Components of Drug Pricing System in Saudi Arabia
Figure 1-6: Burden of Communicable & Non Communicable Diseases in Saudi Arabia, 2012 & 2030
Figure 1-7: Leading Causes of Death in Saudi Arabia, 2011
Figure 2-1: Saudi Arabian Branded Drugs Market Value (US$ Billion), 2012-2018
Figure 2-2: Saudi Arabian Generics Drug Market Value (US$ Billion), 2012-2018
Figure 2-3: Saudi Arabian OTC Drug Market(US$ Billion), 2012-2018
Figure 3-1: Share of Saudi Arabia in GCC Pharmaceuticals Market, 2012
Figure 3-2: Government Expenditure on Health as a % of Total Health Expenditure, 2011
Figure 3-3: Expenditure on Health as a % of Total Government Expenditure, 2011
Figure 4-1: Saudi Arabia Drug Approval Process

List of Tables

Table 1-1: Pricing History and Legal Background in Saudi Arabia
Table 1-2: Drug Pricing for Generics
Table 1-3: Drug Pricing for Fixed Combinations

Saudi Arabia Infrastructure Report
BMI View: We significantly downgraded our short-term outlook for the Saudi Arabian construction sector on the back of liquidity in the market severely drying up, following a reduction in government spending. Beyond 2016 the goals of Vision 2030 will be key to opening up the infrastructure market with the potential of private investment
Saudi Arabia Insurance Report
BMI View: Within the non-life segment, growth in premiums through the forecast period will continue to bedriven by developments in two sub-sectors. There should be higher volumes (if not prices) in the motorvehicle insurance sub-sector, thanks to the expansion in the number of vehicles on Saudi Arabia's vehicles.Higher volumes and inflation in heal
Saudi Arabia: Operators Will Focus on Mobile Network Enhancements and Enterprises to Drive Growth
The telecommunications market in Saudi Arabia generated US$18.8bn in service revenue in 2016, an increase over 2015. Mobile data will emerge as the largest revenue-contributing segment by 2020. Over the next five years, operators can benefit from the opportunities existing in offering enterprise services, VoIP and mobile data. Operators are investi
Saudi Arabia Pharmaceuticals and Healthcare Report
BMI View: The combined value of Saudi Arabia's pharmaceutical and healthcare markets is the largest in the Middle East and Africa region. The Kingdom's National Transformation Program, a key part of Vision 2030, reinstates the government's commitment to improving healthcare provision in the country. Nonetheless, the rising burden of non
Saudi Arabia Petrochemicals Report
The Saudi government is targeting national petrochemicals output of 115mn tonnes in 2016, which represents a 46% increase since 2013. There are 26 petrochemicals projects under construction at a cost of USD15bn while another 42 are planned over the next five years at an estimated cost of USD46bn. However, there is the ongoing threat fro

If above report doesn't have the business information suitable for your business, we can provide custom research that would be lucrative for your business or enhance your profession. We leverage most comprehensive, affordable, high-quality custom research which will match exact topic & specifications of your choice.
Please visit Custom Research page to make an enquiry.

Custom Research

Contact Us

808, Real Tech Park, 8th Floor, Sector 30A, Vashi, Navi Mumbai - 400703 , INDIA .

+91 22 27810772, 27810773